Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CareDx, Inc. (CDNA)

CareDx closes $161.8 million Naveris acquisition and sells Lab Products unit to Eurobio

Neutral Impact 4 of 5 m&a Written later

CareDx completed the sale of its Lab Products business to Eurobio Scientific on June 30, 2026, and the acquisition of Naveris, maker of the NavDx cancer test, on July 1, 2026. The company will include Naveris in its consolidated results from the third quarter of 2026, and it plans to give financial impact details on the sale during its second quarter 2026 earnings call.

Key points

  • Eurobio sale closed June 30, 2026; the 8-K reports $171.7 million in cash, subject to customary adjustments, while the press release cites $171.2 million at closing.
  • Naveris acquisition closed July 1, 2026, for $161.8 million in cash, subject to adjustments, plus up to $100.0 million in contingent cash tied to 2026 and 2027 revenue milestones.
  • The press release says Naveris generated approximately $35 million in revenue in 2025 and that NavDx has Medicare coverage for HPV-driven head and neck and anal cancer MRD testing.
  • Financial statements of Naveris and pro forma information will be filed by amendment within 71 calendar days.

The filing

CompanyCareDx, Inc. (CDNA)
Form8-K, current report
Filed with the SECJul 7, 2026, 5:12 PM ET
Accession number0001217234-26-000038

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.